{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:22:55Z","timestamp":1792264975234,"version":"4.4.0"},"reference-count":221,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"publisher","award":["2021YFC2700303"],"award-info":[{"award-number":["2021YFC2700303"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82225019"],"award-info":[{"award-number":["82225019"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82192873"],"award-info":[{"award-number":["82192873"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["HH22KYZX000"],"award-info":[{"award-number":["HH22KYZX000"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Huntington\u2019s disease (HD) is an inherited neurodegenerative disorder caused by the abnormal expansion of CAG trinucleotide repeats in the Huntingtin gene (HTT) located on chromosome 4. It is transmitted in an autosomal dominant manner and is characterized by motor dysfunction, cognitive decline, and emotional disturbances. To date, there are no curative treatments for HD have been developed; current therapeutic approaches focus on symptom relief and comprehensive care through coordinated pharmacological and nonpharmacological methods to manage the diverse phenotypes of the disease. International clinical guidelines for the treatment of HD are continually being revised in an effort to enhance care within a multidisciplinary framework. Additionally, innovative gene and cell therapy strategies are being actively researched and developed to address the complexities of the disorder and improve treatment outcomes. This review endeavours to elucidate the current and emerging gene and cell therapy strategies for HD, offering a detailed insight into the complexities of the disorder and looking forward to future treatment paradigms. Considering the complexity of the underlying mechanisms driving HD, a synergistic treatment strategy that integrates various factors\u2014such as distinct cell types, epigenetic patterns, genetic components, and methods to improve the cerebral microenvironment\u2014may significantly enhance therapeutic outcomes. In the future, we eagerly anticipate ongoing innovations in interdisciplinary research that will bring profound advancements and refinements in the treatment of HD.<\/jats:p>","DOI":"10.1093\/procel\/pwae042","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T21:01:38Z","timestamp":1723237298000},"page":"307-337","source":"Crossref","is-referenced-by-count":19,"title":["Advances in gene and cellular therapeutic approaches for Huntington\u2019s disease"],"prefix":"10.1093","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1671-242X","authenticated-orcid":false,"given":"Xuejiao","family":"Piao","sequence":"first","affiliation":[{"name":"Clinical Stem Cell Research Center, Peking University Third Hospital , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Stem Cell Research Center, Peking University Third Hospital , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Stem Cell Research Center, Peking University Third Hospital , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Guo","sequence":"additional","affiliation":[{"name":"Clinical Stem Cell Research Center, Peking University Third Hospital , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4310-1966","authenticated-orcid":false,"given":"Yang","family":"Yu","sequence":"additional","affiliation":[{"name":"Clinical Stem Cell Research Center, Peking University Third Hospital , Beijing 100191 ,","place":["China"]},{"name":"Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology and Key Laboratory of Assisted Reproduction, Ministry of Education, Center of Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital , Beijing 100191 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"2025052902313059500_CIT0002","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/15353702211046927","article-title":"Management of altered metabolic activity in","volume":"247","author":"Aditi","year":"2022","journal-title":"Exp Biol Med (Maywood)"},{"key":"2025052902313059500_CIT0003","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.36948\/ijfmr.2023.v05i05.6647","article-title":"Revolutionizing gene therapy: biomaterials as enabling tools for targeted delivery and enhanced efficacy","volume":"5","author":"Agarwal","year":"2023","journal-title":"Int J Multidiscip Res"},{"key":"2025052902313059500_CIT0004","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13024-016-0128-x","article-title":"Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice","volume":"11","author":"Agust\u00edn-Pav\u00f3n","year":"2016","journal-title":"Mol Neurodegener"},{"key":"2025052902313059500_CIT0005","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/brain\/awae063","article-title":"A CAG repeat threshold for therapeutics targeting somatic instability in Huntington\u2019s disease","volume":"147","author":"Aldous","year":"2024","journal-title":"Brain"},{"key":"2025052902313059500_CIT0006","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.15252\/emmm.201707763","article-title":"Disease-modifying effects of ganglioside GM1 in Huntington\u2019s disease models","volume":"9","author":"Alpaugh","year":"2017","journal-title":"EMBO Mol Med"},{"key":"2025052902313059500_CIT0007","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.stem.2012.04.026","article-title":"Genetic correction of Huntington\u2019s disease phenotypes in induced pluripotent stem cells","volume":"11","author":"An","year":"2012","journal-title":"Cell Stem Cell"},{"key":"2025052902313059500_CIT0008","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41586-023-06594-4","article-title":"Design and testing of a humanized porcine donor for xenotransplantation","volume":"622","author":"Anand","year":"2023","journal-title":"Nature"},{"key":"2025052902313059500_CIT0009","doi-asserted-by":"crossref","first-page":"919","DOI":"10.4103\/1673-5374.133133","article-title":"Intravenous transplantation of bone marrow mesenchymal stem cells promotes neural regeneration after traumatic brain injury","volume":"9","author":"Anbari","year":"2014","journal-title":"Neural Regen Res"},{"key":"2025052902313059500_CIT0123","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41587-022-01335-w","article-title":"Lipophilic siRNA conjugates yield durable silencing in extrahepatic tissues","volume":"40","author":"Anonymous","year":"2022","journal-title":"Nat Biotechnol"},{"key":"2025052902313059500_CIT0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"2025052902313059500_CIT0011","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2025052902313059500_CIT0012","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/jnnp.2010.208264","article-title":"Longitudinal change in regional brain volumes in prodromal Huntington disease","volume":"82","author":"Aylward","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025052902313059500_CIT0013","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/mds.28201","article-title":"Human fetal cell therapy in Huntington\u2019s disease: A Randomized, Multicenter, Phase II Trial","volume":"35","author":"Bachoud-L\u00e9vi","year":"2020","journal-title":"Mov Disord"},{"key":"2025052902313059500_CIT0014","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(00)03310-9","article-title":"Motor and cognitive improvements in patients with Huntington\u2019s disease after neural transplantation","volume":"356","author":"Bachoud-L\u00e9vi","year":"2000","journal-title":"Lancet"},{"key":"2025052902313059500_CIT0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1474-4422(06)70381-7","article-title":"Effect of fetal neural transplants in patients with Huntington\u2019s disease 6 years after surgery: a long-term follow-up study","volume":"5","author":"Bachoud-L\u00e9vi","year":"2006","journal-title":"Lancet Neurol"},{"key":"2025052902313059500_CIT0016","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/stem.3300","article-title":"Cell therapy in Huntington\u2019s disease: taking stock of past studies to move the field forward","volume":"39","author":"Bachoud-L\u00e9vi","year":"2021","journal-title":"Stem Cells"},{"key":"2025052902313059500_CIT0017","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrg1557","article-title":"The centrosome in human genetic disease","volume":"6","author":"Badano","year":"2005","journal-title":"Nat Rev Genet"},{"key":"2025052902313059500_CIT0018","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jnnp-2012-302441","article-title":"The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington\u2019s disease","volume":"84","author":"Barker","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025052902313059500_CIT0019","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/brain\/awae105","article-title":"More than 185 CAG repeats: a point of no return in Huntington\u2019s disease biology","volume":"147","author":"Belgrad","year":"2024","journal-title":"Brain"},{"key":"2025052902313059500_CIT000206","article-title":"Bredlau A-L, Bhattacharyya A","author":"Beers","year":"2022"},{"key":"2025052902313059500_CIT0020","doi-asserted-by":"crossref","first-page":"11758","DOI":"10.1038\/ncomms11758","article-title":"Human glia can both induce and rescue aspects of disease phenotype in Huntington disease","volume":"7","author":"Benraiss","year":"2016","journal-title":"Nat Commun"},{"key":"2025052902313059500_CIT0021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/0972-2327.175425","article-title":"The story of George Huntington and his disease","volume":"19","author":"Bhattacharyya","year":"2016","journal-title":"Ann Indian Acad Neurol"},{"key":"2025052902313059500_CIT0022","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jconrel.2020.12.051","article-title":"Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington\u2019s disease","volume":"330","author":"Birolini","year":"2021","journal-title":"J Control Release"},{"key":"2025052902313059500_CIT0023","article-title":"Understanding the treatment and post-treatment effects of tominersen in the Phase III GENERATION HD1 study","author":"Boak","year":"2022"},{"key":"2025052902313059500_CIT0024","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-genet-112618-043515","article-title":"Microglia in brain development, homeostasis, and neurodegeneration","volume":"53","author":"Bohlen","year":"2019","journal-title":"Annu Rev Genet"},{"key":"2025052902313059500_CIT0025","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat Biotechnol"},{"key":"2025052902313059500_CIT0026","article-title":"A new approach to HTT lowering using a C16-siRNA conjugate","author":"Cantley","year":"2023"},{"key":"2025052902313059500_CIT0027","first-page":"36","article-title":"Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease","volume":"48","author":"Caron","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2025052902313059500_CIT0028","article-title":"Targeting the brain with novel AAV capsid variants to reduce mutant HTT and MSH3 with siRNA-based gene therapy for Huntington\u2019s disease","author":"Carter","year":"2023"},{"key":"2025052902313059500_CIT0029","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1091\/mbc.e10-03-0233","article-title":"Huntingtin coordinates the dynein-mediated dynamic positioning of endosomes and lysosomes","volume":"22","author":"Caviston","year":"2011","journal-title":"Mol Biol Cell"},{"key":"2025052902313059500_CIT0030","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1212\/WNL.0000000000011121","article-title":"Association of dilated perivascular spaces and disease severity in patients with huntington disease","volume":"96","author":"Chan","year":"2021","journal-title":"Neurology"},{"key":"2025052902313059500_CIT0031","doi-asserted-by":"crossref","first-page":"R84","DOI":"10.1093\/hmg\/ddn104","article-title":"Cellular repair of CNS disorders: an immunological perspective","volume":"17","author":"Chen","year":"2008","journal-title":"Hum Mol Genet"},{"key":"2025052902313059500_CIT0032","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ymthe.2019.09.003","article-title":"A NeuroD1 AAV-Based Gene Therapy for functional brain repair after ischemic injury through in vivo astrocyte-to-neuron conversion","volume":"28","author":"Chen","year":"2020","journal-title":"Mol Ther"},{"key":"2025052902313059500_CIT0033","doi-asserted-by":"crossref","first-page":"e3001868","DOI":"10.1371\/journal.pbio.3001868","article-title":"Human striatal organoids derived from pluripotent stem cells recapitulate striatal development and compartments","volume":"20","author":"Chen","year":"2022","journal-title":"PLoS Biol"},{"key":"2025052902313059500_CIT0034","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41536-019-0066-7","article-title":"Combination of stem cell and gene therapy ameliorates symptoms in Huntington\u2019s disease mice","volume":"4","author":"Cho","year":"2019","journal-title":"NPJ Regen Med"},{"key":"2025052902313059500_CIT0225","article-title":"Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington\u2019s disease","volume":"12","author":"Choi","year":"2023","journal-title":"eLife"},{"key":"2025052902313059500_CIT0036","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/TA.0b013e318265d128","article-title":"Effects of secretome obtained from normoxia-preconditioned human mesenchymal stem cells in traumatic brain injury rats","volume":"73","author":"Chuang","year":"2012","journal-title":"J Trauma Acute Care Surg"},{"key":"2025052902313059500_CIT0037","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ebiom.2019.09.020","article-title":"A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes","volume":"48","author":"Ciosi","year":"2019","journal-title":"EBioMedicine"},{"key":"2025052902313059500_CIT0038","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3727\/096368913X668636","article-title":"Single-cell suspension methodology favors survival and vascularization of fetal striatal grafts in the YAC128 mouse model of Huntington\u2019s disease","volume":"23","author":"Cisbani","year":"2014","journal-title":"Cell Transplant"},{"key":"2025052902313059500_CIT0039","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/emboj.2008.133","article-title":"Huntingtin phosphorylation acts as a molecular switch for anterograde\/retrograde transport in neurons","volume":"27","author":"Colin","year":"2008","journal-title":"EMBO J"},{"key":"2025052902313059500_CIT0040","doi-asserted-by":"crossref","first-page":"34725","DOI":"10.1021\/acsami.9b12319","article-title":"Selenium nanoparticles as an efficient nanomedicine for the therapy of Huntington\u2019s disease","volume":"11","author":"Cong","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"key":"2025052902313059500_CIT0041","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/stem.2747","article-title":"Concise review: the use of stem cells for understanding and treating Huntington\u2019s disease","volume":"36","author":"Connor","year":"2018","journal-title":"Stem Cells"},{"key":"2025052902313059500_CIT0042","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","article-title":"Identification of genetic factors that modify clinical onset of Huntington\u2019s disease","volume":"162","author":"Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium","year":"2015","journal-title":"Cell"},{"key":"2025052902313059500_CIT0043","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s13346-016-0319-6","article-title":"Computational pharmacokinetic rationale for intra-arterial delivery to the brain","volume":"6","author":"Cooke","year":"2016","journal-title":"Drug Deliv Transl Res"},{"key":"2025052902313059500_CIT0044","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current pharmacological approaches to reduce chorea in Huntington\u2019s disease","volume":"77","author":"Coppen","year":"2017","journal-title":"Drugs"},{"key":"2025052902313059500_CIT0045","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.4103\/1673-5374.390969","article-title":"Therapeutic advances in neural regeneration for Huntington\u2019s disease","volume":"19","author":"D\u2019egidio","year":"2024","journal-title":"Neural Regen Res"},{"key":"2025052902313059500_CIT0046","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fnins.2018.00075","article-title":"Precise excision of the CAG tract from the Huntingtin gene by Cas9 Nickases","volume":"12","author":"Dabrowska","year":"2018","journal-title":"Front Neurosci"},{"key":"2025052902313059500_CIT0047","doi-asserted-by":"crossref","first-page":"e0171127","DOI":"10.1371\/journal.pone.0171127","article-title":"The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain","volume":"12","author":"Datson","year":"2017","journal-title":"PLoS One"},{"key":"2025052902313059500_CIT0048","doi-asserted-by":"crossref","first-page":"24126","DOI":"10.1021\/acsami.7b06510","article-title":"Poly(trehalose) nanoparticles prevent amyloid aggregation and suppress polyglutamine aggregation in a Huntington\u2019s Disease Model Mouse","volume":"9","author":"Debnath","year":"2017","journal-title":"ACS Appl Mater Interfaces"},{"key":"2025052902313059500_CIT0049","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bbr.2010.05.023","article-title":"Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington\u2019s disease","volume":"214","author":"Dey","year":"2010","journal-title":"Behav Brain Res"},{"key":"2025052902313059500_CIT0050","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3233\/JHD-230595","article-title":"Amendment of altered immune response by curcumin in Drosophila model of Huntington\u2019s disease","volume":"12","author":"Dhankhar","year":"2023","journal-title":"J Huntingtons Dis"},{"key":"2025052902313059500_CIT0051","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/mt.2016.126","article-title":"Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing","volume":"24","author":"Didiot","year":"2016","journal-title":"Mol Ther"},{"key":"2025052902313059500_CIT0052","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3727\/096368912X655091","article-title":"Neural stem cells and stroke","volume":"22","author":"Ding","year":"2013","journal-title":"Cell Transplant"},{"key":"2025052902313059500_CIT0053","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1073\/pnas.1114502109","article-title":"Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice","volume":"109","author":"Di Pardo","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025052902313059500_CIT0054","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"2025052902313059500_CIT0055","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.neuroimage.2006.05.057","article-title":"Distribution of grey matter atrophy in Huntington\u2019s disease patients: a combined ROI-based and voxel-based morphometric study","volume":"32","author":"Douaud","year":"2006","journal-title":"Neuroimage"},{"key":"2025052902313059500_CIT0056","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/s41598-024-52667-3","article-title":"Dose-dependent reduction of somatic expansions but not Htt aggregates by di-valent siRNA-mediated silencing of MSH3 in HdhQ111 mice","volume":"14","author":"Driscoll","year":"2024","journal-title":"Sci Rep"},{"key":"2025052902313059500_CIT0057","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1039\/D0NR07622H","article-title":"Exosome-mediated delivery of gene vectors for gene therapy","volume":"13","author":"Duan","year":"2021","journal-title":"Nanoscale"},{"key":"2025052902313059500_CIT0058","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.3390\/polym15092196","article-title":"Nanoparticle-based drug delivery systems: an inspiring therapeutic strategy for neurodegenerative diseases","volume":"15","author":"Duan","year":"2023","journal-title":"Polymers (Basel)"},{"key":"2025052902313059500_CIT0059","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tins.2023.02.005","article-title":"The potential of gene editing for Huntington\u2019s disease","volume":"46","author":"Duan","year":"2023","journal-title":"Trends Neurosci"},{"key":"2025052902313059500_CIT0060","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1126\/science.1072613","article-title":"Sp1 and TAFII130 transcriptional activity disrupted in early Huntington\u2019s disease","volume":"296","author":"Dunah","year":"2002","journal-title":"Science"},{"key":"2025052902313059500_CIT0061","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ng0893-387","article-title":"Trinucleotide repeat length instability and age of onset in Huntington\u2019s disease","volume":"4","author":"Duyao","year":"1993","journal-title":"Nat Genet"},{"key":"2025052902313059500_CIT0062","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.expneurol.2010.03.005","article-title":"Ex vivo delivery of GDNF maintains motor function and prevents neuronal loss in a transgenic mouse model of Huntington\u2019s disease","volume":"224","author":"Ebert","year":"2010","journal-title":"Exp Neurol"},{"key":"2025052902313059500_CIT0063","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","article-title":"CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington\u2019s Disease Mouse Model","volume":"17","author":"Ekman","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"2025052902313059500_CIT0064","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.stemcr.2014.02.011","article-title":"Huntingtin regulates mammary stem cell division and differentiation","volume":"2","author":"Elias","year":"2014","journal-title":"Stem Cell Rep"},{"key":"2025052902313059500_CIT0065","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/JHD-239001","article-title":"Huntington\u2019s disease clinical trials corner: August 2023","volume":"12","author":"Estevez-Fraga","year":"2023","journal-title":"J Huntingtons Dis"},{"key":"2025052902313059500_CIT000204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-240017","article-title":"Huntington\u2019s disease clinical trials corner: March 2024","volume":"13","author":"Estevez-Fraga","year":"2024","journal-title":"J Huntingtons Dis"},{"key":"2025052902313059500_CIT0066","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1136\/jnnp-2012-304636","article-title":"Prevalence of adult Huntington\u2019s disease in the UK based on diagnoses recorded in general practice records","volume":"84","author":"Evans","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025052902313059500_CIT0067","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/14712598.2020.1792880","article-title":"AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins","volume":"20","author":"Evers","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2025052902313059500_CIT0068","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc Chem Res"},{"key":"2025052902313059500_CIT0069","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature20113","article-title":"Transplanted embryonic neurons integrate into adult neocortical circuits","volume":"539","author":"Falkner","year":"2016","journal-title":"Nature"},{"key":"2025052902313059500_CIT0070","doi-asserted-by":"crossref","first-page":"11795735221092517","DOI":"10.1177\/11795735221092517","article-title":"Current and possible future therapeutic options for Huntington\u2019s disease","volume":"14","author":"Ferguson","year":"2022","journal-title":"J Cent Nerv Syst Dis"},{"key":"2025052902313059500_CIT0071","doi-asserted-by":"crossref","first-page":"120714","DOI":"10.1016\/j.ijpharm.2021.120714","article-title":"Nose-to-brain co-delivery of drugs for glioblastoma treatment using nanostructured system","volume":"603","author":"Ferreira","year":"2021","journal-title":"Int J Pharm"},{"key":"2025052902313059500_CIT0072","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3727\/096368916X690863","article-title":"Allele-specific reduction of the mutant Huntingtin allele using transcription activator-like effectors in human Huntington\u2019s disease fibroblasts","volume":"25","author":"Fink","year":"2016","journal-title":"Cell Transplant"},{"key":"2025052902313059500_CIT0073","doi-asserted-by":"crossref","first-page":"a007476","DOI":"10.1101\/cshperspect.a007476","article-title":"Huntington's disease","volume":"3","author":"Finkbeiner","year":"2011","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2025052902313059500_CIT0074","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mds.25717","article-title":"Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk","volume":"29","author":"Fisher","year":"2014","journal-title":"Mov Disord"},{"key":"2025052902313059500_CIT0075","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/brain\/awz115","article-title":"MSH3 modifies somatic instability and disease severity in Huntington\u2019s and myotonic dystrophy type 1","volume":"142","author":"Flower","year":"2019","journal-title":"Brain"},{"key":"2025052902313059500_CIT0076","first-page":"29785","article-title":"Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products. Final rule","volume":"69","author":"Food and Drug Administration HHS","year":"2004","journal-title":"Fed Regist"},{"key":"2025052902313059500_CIT0077","first-page":"40512","article-title":"Revisions to exceptions applicable to certain human cells, tissues, and cellular and tissue-based products. final rule","volume":"81","author":"Food and Drug Administration HHS","year":"2016","journal-title":"Fed Regist"},{"key":"2025052902313059500_CIT0078","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fnhum.2017.00017","article-title":"Contribution of neuroepigenetics to Huntington\u2019s disease","volume":"11","author":"Francelle","year":"2017","journal-title":"Front Hum Neurosci"},{"key":"2025052902313059500_CIT0079","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","article-title":"Treatment of Huntington\u2019s disease","volume":"11","author":"Frank","year":"2014","journal-title":"Neurotherapeutics"},{"key":"2025052902313059500_CIT0080","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(23)00127-8","article-title":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Furr Stimming","year":"2023","journal-title":"Lancet Neurol"},{"key":"2025052902313059500_CIT0081","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/jmg.2009.066399","article-title":"Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors","volume":"46","author":"Futter","year":"2009","journal-title":"J Med Genet"},{"key":"2025052902313059500_CIT0082","doi-asserted-by":"crossref","first-page":"E3136","DOI":"10.1073\/pnas.1206506109","article-title":"Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6\/2 mice","volume":"109","author":"Garriga-Canut","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025052902313059500_CIT0083","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/brain\/awh003","article-title":"Striatal neural grafting improves cortical metabolism in Huntington\u2019s disease patients","volume":"127","author":"Gaura","year":"2004","journal-title":"Brain"},{"key":"2025052902313059500_CIT0084","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2004.06.018","article-title":"Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules","volume":"118","author":"Gauthier","year":"2004","journal-title":"Cell"},{"key":"2025052902313059500_CIT0086","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13287-023-03264-0","article-title":"Mesenchymal stromal cell-derived secretome-based therapy for neurodegenerative diseases: overview of clinical trials","volume":"14","author":"Ghasemi","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"2025052902313059500_CIT0087","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.brainres.2014.06.011","article-title":"YAC128 Huntington\u2019s disease transgenic mice show enhanced short-term hippocampal synaptic plasticity early in the course of the disease","volume":"1581","author":"Ghilan","year":"2014","journal-title":"Brain Res"},{"key":"2025052902313059500_CIT0088","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/jcmm.14113","article-title":"Conditioned medium from amniotic cells protects striatal degeneration and ameliorates motor deficits in the R6\/2 mouse model of Huntington\u2019s disease","volume":"23","author":"Giamp\u00e0","year":"2019","journal-title":"J Cell Mol Med"},{"key":"2025052902313059500_CIT0089","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.neuron.2010.06.027","article-title":"Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis","volume":"67","author":"Godin","year":"2010","journal-title":"Neuron"},{"key":"2025052902313059500_CIT0090","doi-asserted-by":"crossref","first-page":"8157","DOI":"10.1007\/s12035-019-01663-0","article-title":"The therapeutic potential of mesenchymal stem cell-derived exosomes in treatment of neurodegenerative diseases","volume":"56","author":"Gorabi","year":"2019","journal-title":"Mol Neurobiol"},{"key":"2025052902313059500_CIT0091","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.stem.2013.12.001","article-title":"In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer\u2019s disease model","volume":"14","author":"Guo","year":"2014","journal-title":"Cell Stem Cell"},{"key":"2025052902313059500_CIT0092","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature25502","article-title":"The cryo-electron microscopy structure of Huntingtin","volume":"555","author":"Guo","year":"2018","journal-title":"Nature"},{"key":"2025052902313059500_CIT0093","doi-asserted-by":"crossref","first-page":"1143157","DOI":"10.3389\/fbioe.2023.1143157","article-title":"Off-target effects in CRISPR\/Cas9 gene editing","volume":"11","author":"Guo","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"2025052902313059500_CIT0094","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","article-title":"CAG repeat not Polyglutamine length determines timing of Huntington\u2019s disease onset","volume":"178","author":"Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium","year":"2019","journal-title":"Cell"},{"key":"2025052902313059500_CIT0095","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.expneurol.2005.07.026","article-title":"Long-term survival and integration of porcine expanded neural precursor cell grafts in a rat model of Parkinson\u2019s disease","volume":"197","author":"Harrower","year":"2006","journal-title":"Exp Neurol"},{"key":"2025052902313059500_CIT0096","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.88.16_supplement.P2.006","article-title":"Multicenter, randomized, double-blind, placebo-controlled phase 1b\/2a studies of WVE-120101 and WVE-120102 in patients with Huntington\u2019s Disease","author":"Hersch","year":"2017"},{"key":"2025052902313059500_CIT0097","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41593-018-0242-x","article-title":"Microglia in neurodegeneration","volume":"21","author":"Hickman","year":"2018","journal-title":"Nat Neurosci"},{"key":"2025052902313059500_CIT0098","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1073\/pnas.98.4.1811","article-title":"The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington\u2019s disease pathogenesis","volume":"98","author":"Holbert","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025052902313059500_CIT0099","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/JHD-200427","article-title":"Huntington\u2019s disease pathogenesis: two sequential components","volume":"10","author":"Hong","year":"2021","journal-title":"J Huntingtons Dis"},{"key":"2025052902313059500_CIT0100","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41596-020-00450-9","article-title":"Precision genome editing using cytosine and adenine base editors in mammalian cells","volume":"16","author":"Huang","year":"2021","journal-title":"Nat Protoc"},{"key":"2025052902313059500_CIT0226","volume":"1","author":"Huntington disease","year":"2015","journal-title":"Nature Reviews Disease Primers"},{"key":"2025052902313059500_CIT0101","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s12033-009-9166-8","article-title":"Cell therapy for CNS trauma","volume":"42","author":"Jain","year":"2009","journal-title":"Mol Biotechnol"},{"key":"2025052902313059500_CIT0102","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/stem.1135","article-title":"Neuronal properties, in vivo effects, and pathology of a Huntington\u2019s disease patient-derived induced pluripotent stem cells","volume":"30","author":"Jeon","year":"2012","journal-title":"Stem Cells"},{"key":"2025052902313059500_CIT0103","doi-asserted-by":"crossref","first-page":"e30293","DOI":"10.1371\/journal.pone.0030293","article-title":"Colloids as mobile substrates for the implantation and integration of differentiated neurons into the mammalian brain","volume":"7","author":"Jgamadze","year":"2012","journal-title":"PLoS One"},{"key":"2025052902313059500_CIT0104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcyt.2021.02.008","article-title":"A Phase I clinical trial on intravenous administration of immature human dental pulp stem cells (Nestacell Hdtm) to Huntington\u2019s disease patients","volume":"23","author":"Joao","year":"2021","journal-title":"Cytotherapy"},{"key":"2025052902313059500_CIT0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/B978-0-12-381328-2.00015-8","article-title":"Pathogenic mechanisms in Huntington\u2019s disease","volume":"98","author":"Jones","year":"2011","journal-title":"Int Rev Neurobiol"},{"key":"2025052902313059500_CIT0106","first-page":"3","article-title":"The effects of huntingtin-lowering: what do we know so far","volume":"9","author":"Kaemmerer","year":"2019","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"2025052902313059500_CIT0107","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cge.12385","article-title":"Personalized gene silencing therapeutics for Huntington disease","volume":"86","author":"Kay","year":"2014","journal-title":"Clin Genet"},{"key":"2025052902313059500_CIT0108","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/mt.2015.128","article-title":"Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in Huntington disease patients of European Ancestry","volume":"23","author":"Kay","year":"2015","journal-title":"Mol Ther"},{"key":"2025052902313059500_CIT000203","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/s41467-022-28653-6","article-title":"An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion","volume":"13","author":"Keller","year":"2022","journal-title":"Nat Commun"},{"key":"2025052902313059500_CIT0110","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI57552","article-title":"Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease","volume":"121","author":"Keryer","year":"2011","journal-title":"J Clin Invest"},{"key":"2025052902313059500_CIT0111","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.omtm.2019.09.010","article-title":"AAV5-miHTT lowers Huntingtin mRNA and protein without off-target effects in patient-derived neuronal cultures and astrocytes","volume":"15","author":"Keskin","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025052902313059500_CIT0112","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1073\/pnas.93.3.1156","article-title":"Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain","volume":"93","author":"Kim","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025052902313059500_CIT0113","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.3390\/ijms22168363","article-title":"New avenues for the treatment of Huntington\u2019s disease","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025052902313059500_CIT0114","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.3727\/096368911X566190","article-title":"Injection parameters affect cell viability and implant volumes in automated cell delivery for the brain","volume":"20","author":"Kondziolka","year":"2011","journal-title":"Cell Transplant"},{"key":"2025052902313059500_CIT0115","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3171\/jns.2005.103.5.0923","article-title":"Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents","volume":"103","author":"Krauze","year":"2005","journal-title":"J Neurosurg"},{"key":"2025052902313059500_CIT0116","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14802\/jmd.16054","article-title":"Exosome-based delivery of miR-124 in a Huntington\u2019s Disease Model","volume":"10","author":"Lee","year":"2017","journal-title":"J Mov Disord"},{"key":"2025052902313059500_CIT0117","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1056\/NEJMra1806175","article-title":"Organoids - Preclinical models of human disease. Reply","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"2025052902313059500_CIT0118","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"},{"key":"2025052902313059500_CIT0119","doi-asserted-by":"crossref","first-page":"1109967","DOI":"10.1155\/2023\/1109967","article-title":"Mesenchymal stem cell therapy for Huntington disease: a meta-analysis","volume":"2023","author":"Liang","year":"2023","journal-title":"Stem Cells Int"},{"key":"2025052902313059500_CIT0120","doi-asserted-by":"crossref","first-page":"e22924","DOI":"10.1371\/journal.pone.0022924","article-title":"Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington\u2019s disease mouse models","volume":"6","author":"Lin","year":"2011","journal-title":"PLoS One"},{"key":"2025052902313059500_CIT0121","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.expneurol.2016.04.003","article-title":"Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington\u2019s disease","volume":"281","author":"Linares","year":"2016","journal-title":"Exp Neurol"},{"key":"2025052902313059500_CIT0122","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1523\/JNEUROSCI.2033-12.2013","article-title":"Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites","volume":"33","author":"Liot","year":"2013","journal-title":"J Neurosci"},{"key":"2025052902313059500_CIT0124","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.molcel.2021.12.002","article-title":"The CRISPR-Cas toolbox and gene editing technologies","volume":"82","author":"Liu","year":"2022","journal-title":"Mol Cell"},{"key":"2025052902313059500_CIT0125","doi-asserted-by":"crossref","first-page":"13205","DOI":"10.1021\/acs.jmedchem.3c01173","article-title":"Identification and optimization of RNA-splicing modulators as Huntingtin protein-lowering agents for the treatment of Huntington\u2019s disease","volume":"66","author":"Liu","year":"2023","journal-title":"J Med Chem"},{"key":"2025052902313059500_CIT0126","doi-asserted-by":"crossref","first-page":"576592","DOI":"10.3389\/fcell.2020.576592","article-title":"Mitochondrial and redox modifications in Huntington disease induced pluripotent stem cells rescued by CRISPR\/Cas9 CAGs targeting","volume":"8","author":"Lopes","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2025052902313059500_CIT0127","doi-asserted-by":"crossref","first-page":"eabd5758","DOI":"10.1126\/scitranslmed.abd5758","article-title":"Importance of the pig as a human biomedical model","volume":"13","author":"Lunney","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025052902313059500_CIT0128","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/med.22002","article-title":"Translating mesenchymal stem cell and their exosome research into GMP compliant advanced therapy products: promises, problems and prospects","volume":"44","author":"Ma","year":"2023","journal-title":"Med Res Rev"},{"key":"2025052902313059500_CIT0129","doi-asserted-by":"crossref","first-page":"877","DOI":"10.5966\/sctm.2016-0269","article-title":"Magnetic resonance imaging-guided delivery of neural stem cells into the Basal Ganglia of nonhuman primates reveals a pulsatile mode of cell dispersion","volume":"6","author":"Malloy","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"2025052902313059500_CIT0131","doi-asserted-by":"crossref","first-page":"9578","DOI":"10.1073\/pnas.1133382100","article-title":"Stimulation of NeuroD activity by huntingtin and huntingtin-associated proteins HAP1 and MLK2","volume":"100","author":"Marcora","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025052902313059500_CIT0133","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM198611133152006","article-title":"Huntington\u2019s disease. Pathogenesis and management","volume":"315","author":"Martin","year":"1986","journal-title":"N Engl J Med"},{"key":"2025052902313059500_CIT0134","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bjps.2019.05.030","article-title":"Adhesion, distribution, and migration of differentiated and undifferentiated mesenchymal stem cells (MSCs) seeded on nerve allografts","volume":"73","author":"Mathot","year":"2020","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2025052902313059500_CIT0135","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.25354","article-title":"Outcome of cell suspension allografts in a patient with Huntington\u2019s disease","volume":"84","author":"Maxan","year":"2018","journal-title":"Ann Neurol"},{"key":"2025052902313059500_CIT0137","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/mdc3.12803","article-title":"Second-generation antisense nucleotide targeting Huntingtin expression found to be safe in patients with Huntington\u2019s disease","volume":"6","author":"Medina Escobar","year":"2019","journal-title":"Mov Disord Clin Pract"},{"key":"2025052902313059500_CIT0138","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1038\/mtna.2016.7","article-title":"Design, characterization, and lead selection of therapeutic miRNAs targeting Huntingtin for development of gene therapy for Huntington\u2019s disease","volume":"5","author":"Miniarikova","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"2025052902313059500_CIT0139","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene Ther"},{"key":"2025052902313059500_CIT0140","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/s41587-020-00763-w","article-title":"Generation of human striatal organoids and cortico-striatal assembloids from human pluripotent stem cells","volume":"38","author":"Miura","year":"2020","journal-title":"Nat Biotechnol"},{"key":"2025052902313059500_CIT0141","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 editing of the mutant Huntingtin allele in vitro and in vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol Ther"},{"key":"2025052902313059500_CIT0142","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41593-022-01207-1","article-title":"An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington\u2019s disease models","volume":"26","author":"Morelli","year":"2023","journal-title":"Nat Neurosci"},{"key":"2025052902313059500_CIT0143","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41467-017-00926-5","article-title":"MHC matching improves engraftment of iPSC-derived neurons in non-human primates","volume":"8","author":"Morizane","year":"2017","journal-title":"Nat Commun"},{"key":"2025052902313059500_CIT0144","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1093\/hmg\/ddaa139","article-title":"Patterns of CAG repeat instability in the central nervous system and periphery in Huntington\u2019s disease and in spinocerebellar ataxia type 1","volume":"29","author":"Mouro Pinto","year":"2020","journal-title":"Hum Mol Genet"},{"key":"2025052902313059500_CIT0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41556-020-00620-7","article-title":"CRISPR technologies for precise epigenome editing","volume":"23","author":"Nakamura","year":"2021","journal-title":"Nat Cell Biol"},{"key":"2025052902313059500_CIT0146","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jmb.2018.06.029","article-title":"Molecular mechanisms of RNA targeting by Cas13-containing Type VI CRISPR-Cas systems","volume":"431","author":"O\u2019connell","year":"2019","journal-title":"J Mol Biol"},{"key":"2025052902313059500_CIT0147","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.ymthe.2023.09.016","article-title":"Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington\u2019s disease","volume":"31","author":"O\u2019reilly","year":"2023","journal-title":"Mol Ther"},{"key":"2025052902313059500_CIT0148","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3727\/096368915X690369","article-title":"Induction of endothelial phenotype from Wharton\u2019s Jelly-Derived MSCs and comparison of their vasoprotective and neuroprotective potential with primary WJ-MSCs in CA1 Hippocampal Region Ex Vivo","volume":"25","author":"Obtulowicz","year":"2016","journal-title":"Cell Transplant"},{"key":"2025052902313059500_CIT0149","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/hum.2020.323","article-title":"Allele-specific knockdown of mutant Huntingtin protein via editing at coding region single nucleotide polymorphism heterozygosities","volume":"33","author":"Oikemus","year":"2022","journal-title":"Hum Gene Ther"},{"key":"2025052902313059500_CIT0150","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nchembio.1837","article-title":"SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice","volume":"11","author":"Palacino","year":"2015","journal-title":"Nat Chem Biol"},{"key":"2025052902313059500_CIT0151","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1126\/science.1202529","article-title":"Synaptic pruning by microglia is necessary for normal brain development","volume":"333","author":"Paolicelli","year":"2011","journal-title":"Science"},{"key":"2025052902313059500_CIT0152","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41536-021-00198-0","article-title":"SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington\u2019s disease","volume":"7","author":"Park","year":"2022","journal-title":"NPJ Regen Med"},{"key":"2025052902313059500_CIT0153","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41586-023-06300-4","article-title":"Co-transplantation of autologous T","volume":"619","author":"Park","year":"2023","journal-title":"Nature"},{"key":"2025052902313059500_CIT0154","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.cell.2013.11.030","article-title":"Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor","volume":"155","author":"Parkhurst","year":"2013","journal-title":"Cell"},{"key":"2025052902313059500_CIT0155","doi-asserted-by":"crossref","first-page":"114199","DOI":"10.1016\/j.expneurol.2022.114199","article-title":"Mesenchymal stromal cell secretome for traumatic brain injury: focus on immunomodulatory action","volume":"357","author":"Pischiutta","year":"2022","journal-title":"Exp Neurol"},{"key":"2025052902313059500_CIT0156","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neuint.2017.01.016","article-title":"Is there a place for human fetal-derived stem cells for cell replacement therapy in Huntington\u2019s disease","volume":"106","author":"Precious","year":"2017","journal-title":"Neurochem Int"},{"key":"2025052902313059500_CIT0157","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.25075","article-title":"The incidence and prevalence of Huntington\u2019s disease: a systematic review and meta-analysis","volume":"27","author":"Pringsheim","year":"2012","journal-title":"Mov Disord"},{"key":"2025052902313059500_CIT0158","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41586-020-2388-4","article-title":"Reversing a model of Parkinson\u2019s disease with in situ converted nigral neurons","volume":"582","author":"Qian","year":"2020","journal-title":"Nature"},{"key":"2025052902313059500_CIT0159","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"key":"2025052902313059500_CIT0160","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1750-3639.1997.tb00893.x","article-title":"The neuropathology of CAG repeat diseases: review and update of genetic and molecular features","volume":"7","author":"Robitaille","year":"1997","journal-title":"Brain Pathol"},{"key":"2025052902313059500_CIT0161","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.stem.2013.11.014","article-title":"An effective approach to prevent immune rejection of human ESC-derived allografts","volume":"14","author":"Rong","year":"2014","journal-title":"Cell Stem Cell"},{"key":"2025052902313059500_CIT0162","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40259-022-00519-9","article-title":"Antisense oligonucleotide therapy: from design to the Huntington disease clinic","volume":"36","author":"Rook","year":"2022","journal-title":"BioDrugs"},{"key":"2025052902313059500_CIT0163","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington\u2019s disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol"},{"key":"2025052902313059500_CIT0164","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/jnnp.73.6.678","article-title":"Unilateral transplantation of human primary fetal tissue in four patients with Huntington\u2019s disease: NEST-UK safety report ISRCTN no 36485475","volume":"73","author":"Rosser","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2025052902313059500_CIT0165","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/brain\/awac086","article-title":"Translating cell therapies for neurodegenerative diseases: Huntington\u2019s disease as a model disorder","volume":"145","author":"Rosser","year":"2022","journal-title":"Brain"},{"key":"2025052902313059500_CIT0166","doi-asserted-by":"crossref","first-page":"e4f7f6dc013d4e","DOI":"10.1371\/4f7f6dc013d4e","article-title":"Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6\/2 transgenic mouse model for Huntington\u2019s disease","volume":"4","author":"Sadan","year":"2012","journal-title":". PLoS Curr"},{"key":"2025052902313059500_CIT000201","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11910-024-01345-y","article-title":"Huntington\u2019s disease: Latest frontiers in therapeutics","volume":"24","author":"Saade","year":"2024","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2025052902313059500_CIT0167","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.expneurol.2011.12.045","article-title":"Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington\u2019s disease","volume":"234","author":"Sadan","year":"2012","journal-title":"Exp Neurol"},{"key":"2025052902313059500_CIT0168","first-page":"1822","article-title":"Stem cell therapy in neurodegenerative diseases: from principles to practice","volume":"7","author":"Sakthiswary","year":"2012","journal-title":"Neural Regen Res"},{"key":"2025052902313059500_CIT0169","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"2025052902313059500_CIT0170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13287-023-03422-4","article-title":"hESC-derived striatal progenitors grafted into a Huntington\u2019s disease rat model support long-term functional motor recovery by differentiating, self-organizing and connecting into the lesioned striatum","volume":"14","author":"Schellino","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"2025052902313059500_CIT0171","article-title":"Preliminary results from GENERATION HD1, a phase III trial of tominersen in individuals with manifest HD","author":"Schobel","year":"2021"},{"key":"2025052902313059500_CIT0173","first-page":"4566","article-title":"Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9","volume":"25","author":"Shin","year":"2016","journal-title":"Hum Mol Genet"},{"key":"2025052902313059500_CIT0174","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1192\/bjp.165.4.500","article-title":"controlled psychiatric study of individuals at risk for Huntington\u2019s disease","volume":"165","author":"Shiwach","year":"1994","journal-title":"Br J Psychiatry"},{"key":"2025052902313059500_CIT0175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/mt.2014.155","article-title":"Interventional magnetic resonance imaging-guided cell transplantation into the brain with radially branched deployment","volume":"23","author":"Silvestrini","year":"2015","journal-title":"Mol Ther"},{"key":"2025052902313059500_CIT0176","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3390\/ijms22042153","article-title":"Regenerative stem cell therapy for neurodegenerative diseases: an overview","volume":"22","author":"Sivandzade","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025052902313059500_CIT0177","doi-asserted-by":"crossref","first-page":"e9347","DOI":"10.1371\/journal.pone.0009347","article-title":"Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington\u2019s disease","volume":"5","author":"Snyder","year":"2010","journal-title":"PLoS One"},{"key":"2025052902313059500_CIT0178","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/brainsci11020129","article-title":"Intrastriatal administration of AAV5-miHTT in non-human primates and rats is well tolerated and results in miHTT transgene expression in key areas of Huntington disease pathology","volume":"11","author":"Spronck","year":"2021","journal-title":"Brain Sci"},{"key":"2025052902313059500_CIT0179","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","article-title":"Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease","volume":"25","author":"Stanek","year":"2014","journal-title":"Hum Gene Ther"},{"key":"2025052902313059500_CIT0180","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The Huntington\u2019s disease protein interacts with p53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025052902313059500_CIT0181","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.expneurol.2011.11.020","article-title":"Widespread suppression of huntingtin with convection-enhanced delivery of siRNA","volume":"233","author":"Stiles","year":"2012","journal-title":"Exp Neurol"},{"key":"2025052902313059500_CIT0182","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/hmg\/2.10.1547","article-title":"Correlation between the onset age of Huntington\u2019s disease and length of the trinucleotide repeat in IT-15","volume":"2","author":"Stine","year":"1993","journal-title":"Hum Mol Genet"},{"key":"2025052902313059500_CIT0183","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/B978-0-444-63233-3.00011-7","article-title":"The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology","volume":"147","author":"Stoyas","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"2025052902313059500_CIT0184","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40824-019-0156-z","article-title":"Recent advances in the development of gene delivery systems","volume":"23","author":"Sung","year":"2019","journal-title":"Biomater Res"},{"key":"2025052902313059500_CIT0186","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","article-title":"Potential endpoints for clinical trials in premanifest and early Huntington\u2019s disease in the TRACK-HD study: analysis of 24 month observational data","volume":"11","author":"Tabrizi","year":"2012","journal-title":"Lancet Neurol"},{"key":"2025052902313059500_CIT0187","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.neuron.2019.05.001","article-title":"Huntingtin lowering strategies for disease modification in Huntington\u2019s disease","volume":"102","author":"Tabrizi","year":"2019","journal-title":"Neuron"},{"key":"2025052902313059500_CIT0188","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin expression in patients with Huntington\u2019s disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N Engl J Med"},{"key":"2025052902313059500_CIT000202","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: New insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"2025052902313059500_CIT0189","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","article-title":"Potential disease-modifying therapies for Huntington\u2019s disease: lessons learned and future opportunities","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol"},{"key":"2025052902313059500_CIT0190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fncel.2020.00107","article-title":"Regeneration through","volume":"14","author":"Tai","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"2025052902313059500_CIT0191","doi-asserted-by":"crossref","first-page":"750","DOI":"10.4103\/1673-5374.353482","article-title":"astrocyte-to-neuron reprogramming for central nervous system regeneration: a narrative review","volume":"18","author":"Talifu","year":"2023","journal-title":"Neural Regen Res"},{"key":"2025052902313059500_CIT0192","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/mds.29412","article-title":"CAG repeat expansion in THAP11 is associated with a novel Spinocerebellar Ataxia","volume":"38","author":"Tan","year":"2023","journal-title":"Mov Disord"},{"key":"2025052902313059500_CIT0193","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/d41586-023-02177-5","article-title":"Regulatory T cells aid stem-cell therapy for Parkinson\u2019s disease","volume":"619","author":"Tang","year":"2023","journal-title":"Nature"},{"key":"2025052902313059500_CIT0194","doi-asserted-by":"crossref","first-page":"e1003280","DOI":"10.1371\/journal.pgen.1003280","article-title":"MSH3 polymorphisms and protein levels affect CAG repeat instability in Huntington\u2019s disease mice","volume":"9","author":"Tom\u00e9","year":"2013","journal-title":"PLoS Genet"},{"key":"2025052902313059500_CIT0195","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3727\/096368914X685429","article-title":"Translation of cell therapies to the clinic: characteristics of cell suspensions in large-diameter injection cannulae","volume":"24","author":"Torres","year":"2015","journal-title":"Cell Transplant"},{"key":"2025052902313059500_CIT0197","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","article-title":"Beyond the brain: widespread pathology in Huntington\u2019s disease","volume":"8","author":"Van Der Burg","year":"2009","journal-title":"Lancet Neurol"},{"key":"2025052902313059500_CIT0198","article-title":"A Ph1b\/2a study of WVE-003, an investigational allele-selective, mHTT-lowering oligonucleotide for the treatment of early manifest Huntington\u2019s disease, and review of PRECISION-HD results","author":"Viglietta","year":"2021"},{"key":"2025052902313059500_CIT0199","doi-asserted-by":"crossref","first-page":"60894","DOI":"10.1021\/acsami.1c18754","article-title":"Polyglutamine-specific gold nanoparticle complex alleviates mutant Huntingtin-induced toxicity","volume":"13","author":"Wahyuningtyas","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"2025052902313059500_CIT0200","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/scd.2019.0147","article-title":"Neurogenic Niche conversion strategy induces migration and functional neuronal differentiation of neural precursor cells following brain injury","volume":"29","author":"Wang","year":"2020","journal-title":"Stem Cells Dev"},{"key":"2025052902313059500_CIT0201","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1016\/j.cell.2021.09.005","article-title":"Revisiting astrocyte to neuron conversion with lineage tracing in vivo","volume":"184","author":"Wang","year":"2021","journal-title":"Cell"},{"key":"2025052902313059500_CIT0202","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.bbi.2023.07.011","article-title":"Microglial repopulation reverses cognitive and synaptic deficits in an Alzheimer\u2019s disease model by restoring BDNF signaling","volume":"113","author":"Wang","year":"2023","journal-title":"Brain Behav Immun"},{"key":"2025052902313059500_CIT0203","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.celrep.2016.06.066","article-title":"Neurons differentiated from transplanted stem cells respond functionally to acoustic stimuli in the awake monkey brain","volume":"16","author":"Wei","year":"2016","journal-title":"Cell Rep"},{"key":"2025052902313059500_CIT0204","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3390\/cells11101664","article-title":"Restoration of BDNF, DARPP32, and D2R expression following intravenous infusion of human immature dental pulp stem cells in Huntington\u2019s Disease 3-NP Rat Model","volume":"11","author":"Wenceslau","year":"2022","journal-title":"Cells"},{"key":"2025052902313059500_CIT0205","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol"},{"key":"2025052902313059500_CIT0206","doi-asserted-by":"crossref","first-page":"ENEURO.0063","DOI":"10.1523\/ENEURO.0063-17.2017","article-title":"Anodal transcranial direct current stimulation enhances survival and integration of dopaminergic cell transplants in a Rat Parkinson Model","volume":"4","author":"Winkler","year":"2017","journal-title":"eNeuro"},{"key":"2025052902313059500_CIT0207","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1523\/JNEUROSCI.1870-13.2014","article-title":"The regulation of autophagosome dynamics by huntingtin and HAP1 is disrupted by expression of mutant huntingtin, leading to defective cargo degradation","volume":"34","author":"Wong","year":"2014","journal-title":"J Neurosci"},{"key":"2025052902313059500_CIT0208","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.ajhg.2019.04.007","article-title":"Length of uninterrupted CAG, independent of polyglutamine size, results in increased somatic instability, hastening onset of Huntington disease","volume":"104","author":"Wright","year":"2019","journal-title":"Am J Hum Genet"},{"key":"2025052902313059500_CIT0209","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41467-020-14855-3","article-title":"Gene therapy conversion of striatal astrocytes into GABAergic neurons in mouse models of Huntington\u2019s disease","volume":"11","author":"Wu","year":"2020","journal-title":"Nat Commun"},{"key":"2025052902313059500_CIT0210","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.stemcr.2017.01.022","article-title":"Reversal of phenotypic abnormalities by CRISPR\/Cas9-mediated gene correction in Huntington disease patient-derived induced pluripotent stem cells","volume":"8","author":"Xu","year":"2017","journal-title":"Stem Cell Rep"},{"key":"2025052902313059500_CIT0211","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.stem.2020.09.014","article-title":"Pluripotent stem cell-based cell therapy-promise and challenges","volume":"27","author":"Yamanaka","year":"2020","journal-title":"Cell Stem Cell"},{"key":"2025052902313059500_CIT0212","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cell.2018.03.005","article-title":"A Huntingtin Knockin Pig Model recapitulates features of selective neurodegeneration in Huntington\u2019s disease","volume":"173","author":"Yan","year":"2018","journal-title":"Cell"},{"key":"2025052902313059500_CIT0213","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41551-023-01007-3","article-title":"Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington\u2019s disease","volume":"7","author":"Yan","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"2025052902313059500_CIT0214","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington\u2019s disease","volume":"127","author":"Yang","year":"2017","journal-title":"J Clin Invest"},{"key":"2025052902313059500_CIT0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13024-019-0321-9","article-title":"A CRISPR monkey model unravels a unique function of PINK1 in primate brains","volume":"14","author":"Yang","year":"2019","journal-title":"Mol Neurodegener"},{"key":"2025052902313059500_CIT0216","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1044-7431(03)00032-0","article-title":"Mutant huntingtin increases nuclear corepressor function and enhances ligand-dependent nuclear hormone receptor activation","volume":"23","author":"Yohrling","year":"2003","journal-title":"Mol Cell Neurosci"},{"key":"2025052902313059500_CIT0217","doi-asserted-by":"crossref","first-page":"e60162","DOI":"10.1371\/journal.pone.0060162","article-title":"Huntingtin\u2019s function in axonal transport is conserved in Drosophila melanogaster","volume":"8","author":"Zala","year":"2013","journal-title":"PLoS One"},{"key":"2025052902313059500_CIT0218","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","article-title":"Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington\u2019s disease","volume":"25","author":"Zeitler","year":"2019","journal-title":"Nat Med"},{"key":"2025052902313059500_CIT0219","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pbiomolbio.2013.11.006","article-title":"TALE: a tale of genome editing","volume":"114","author":"Zhang","year":"2014","journal-title":"Prog Biophys Mol Biol"},{"key":"2025052902313059500_CIT0220","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.cell.2018.09.001","article-title":"Structural basis for the RNA-guided ribonuclease activity of CRISPR-Cas13d","volume":"175","author":"Zhang","year":"2018","journal-title":"Cell"},{"key":"2025052902313059500_CIT0221","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.cell.2020.03.024","article-title":"Glia-to-neuron conversion by CRISPR-CasRx alleviates symptoms of neurological disease in mice","volume":"181","author":"Zhou","year":"2020","journal-title":"Cell"},{"key":"2025052902313059500_CIT0222","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1126\/science.1059581","article-title":"Loss of huntingtin-mediated BDNF gene transcription in Huntington\u2019s disease","volume":"293","author":"Zuccato","year":"2001","journal-title":"Science"},{"key":"2025052902313059500_CIT0223","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ng1219","article-title":"Huntingtin interacts with REST\/NRSF to modulate the transcription of NRSE-controlled neuronal genes","volume":"35","author":"Zuccato","year":"2003","journal-title":"Nat Genet"},{"key":"2025052902313059500_CIT0224","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol Rev"}],"container-title":["Protein &amp; Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/proteincell\/advance-article-pdf\/doi\/10.1093\/procel\/pwae042\/60338131\/pwae042.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/proteincell\/article-pdf\/16\/5\/307\/60338131\/pwae042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/proteincell\/article-pdf\/16\/5\/307\/60338131\/pwae042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T06:32:08Z","timestamp":1748500328000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/proteincell\/article\/16\/5\/307\/7731066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":221,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,8,9]]},"published-print":{"date-parts":[[2025,5,28]]}},"URL":"https:\/\/doi.org\/10.1093\/procel\/pwae042","relation":{},"ISSN":["1674-800X","1674-8018"],"issn-type":[{"value":"1674-800X","type":"print"},{"value":"1674-8018","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,8,9]]}}}